NO20073928L - Stabilt partikkelformig legemiddel med solifenacin eller salt av dette - Google Patents

Stabilt partikkelformig legemiddel med solifenacin eller salt av dette

Info

Publication number
NO20073928L
NO20073928L NO20073928A NO20073928A NO20073928L NO 20073928 L NO20073928 L NO 20073928L NO 20073928 A NO20073928 A NO 20073928A NO 20073928 A NO20073928 A NO 20073928A NO 20073928 L NO20073928 L NO 20073928L
Authority
NO
Norway
Prior art keywords
solifenacin
salt
particulate
stable particulate
pharmaceutical composition
Prior art date
Application number
NO20073928A
Other languages
English (en)
Inventor
Hiroyuki Umejima
Hiroshi Ohi
Katsumi Saito
Yuko Taketani
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20073928L publication Critical patent/NO20073928L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Stabil partikkelformig farmasøytisk blanding av solifenacin eller salt derav for anvendelse som et farmasøytisk preparat på det kliniske område. Preparatet er i kuleform egnet for påføring av overtrekk, hvor degradering over tid kan bli inhibert, Det partikkelformige farmasøytiske preparat fremstilles ved å anvende et bindemiddel med Tg eller smp lavere enn 174 0C, ved formuleringen av en partikkelformig blanding med solifenacin til et farmasøytisk preparat. Det utføres behandling som påskynder krystallisasjon etter at den partikkelformige farmasøytiske blanding er dannet, og det oppnås en stabilere partikkelformig blanding med solifenacin eller et salt derav.
NO20073928A 2004-12-27 2007-07-26 Stabilt partikkelformig legemiddel med solifenacin eller salt av dette NO20073928L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63838804P 2004-12-27 2004-12-27
JP2005085968 2005-03-24
PCT/JP2005/023771 WO2006070735A1 (ja) 2004-12-27 2005-12-26 ソリフェナシンまたはその塩の安定な粒子状医薬組成物

Publications (1)

Publication Number Publication Date
NO20073928L true NO20073928L (no) 2007-09-18

Family

ID=36614852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073928A NO20073928L (no) 2004-12-27 2007-07-26 Stabilt partikkelformig legemiddel med solifenacin eller salt av dette

Country Status (8)

Country Link
US (1) US20080103171A1 (no)
EP (1) EP1832288B1 (no)
KR (1) KR101342786B1 (no)
CN (1) CN101141961B (no)
AU (1) AU2005320672B2 (no)
CA (1) CA2591761A1 (no)
NO (1) NO20073928L (no)
WO (1) WO2006070735A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128028A2 (en) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US8568785B2 (en) 2006-07-19 2013-10-29 Asahi Kasei Chemicals Corporation Process for producing spherical base granule comprising easily water-soluble drug
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
MY160652A (en) * 2009-02-04 2017-03-15 Astellas Pharma Inc Pharmaceutical composition for oral administration
US20100273825A1 (en) * 2009-03-30 2010-10-28 Astellas Pharma Inc. Solid pharmaceutical composition containing solifenacin amorphous form
WO2011137877A2 (en) 2010-05-07 2011-11-10 Zentiva K.S. A pharmaceutical composition containing solifenacin and a method of its manufacture
HRP20160901T1 (hr) * 2010-05-19 2016-10-07 Astellas Pharma Inc. Farmaceutski pripravak koji sadrži solifenacin
CA2804107A1 (en) 2010-07-05 2012-01-12 Crystal Pharma S.A.U. Solifenacin salts
US9861577B2 (en) * 2010-08-31 2018-01-09 Kyowa Hakko Kirin Co., Ltd. Orally disintegrating tablet
JP5936542B2 (ja) 2010-09-01 2016-06-22 アステラス製薬株式会社 包装体
WO2012062916A1 (de) 2010-11-11 2012-05-18 Hexal Ag Kristallines solifenacin-succinat
EP2500013B1 (en) 2011-03-15 2019-10-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising solifenacin
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN104940152B (zh) * 2014-03-31 2017-12-29 成都国为生物医药有限公司 一种含有琥珀酸索利那新的药物组合物
JP2016079102A (ja) * 2014-10-10 2016-05-16 テバ製薬株式会社 ソリフェナシン含有製剤
JP6805699B2 (ja) * 2016-10-04 2020-12-23 ニプロ株式会社 医薬組成物、医薬組成物の製造方法、及び非晶質体の安定性を向上させる方法
KR102090135B1 (ko) * 2017-07-14 2020-03-17 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법
KR20210114271A (ko) 2020-03-10 2021-09-23 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물
AU2021265311A1 (en) * 2020-04-27 2022-12-08 Zim Laboratories Limited Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
PL4255398T3 (pl) 2020-12-01 2024-12-09 Adamed Pharma S.A. Podawany doustnie preparat zawierający solifenacynę i tamsulosynę

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4870059A (en) * 1985-11-27 1989-09-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Dehydration of hydrous matter with anhydrous maltose
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DK0538497T3 (da) * 1991-09-25 1994-08-22 Barilla G E R F Ili Societ Per Kuvertbrød, der smager som brød, og fremgangsmåde til fremstilling deraf
TW284688B (no) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
JPH0624001A (ja) 1992-06-05 1994-02-01 Nec Corp インクカートリッジ及びこれを用いたインクジェット記録装置
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
DK1309315T3 (da) * 2000-08-18 2006-10-09 Pharmacia Corp Hurtigt disintegrerende oral valdecoxib-formulering
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
KR20030076634A (ko) * 2001-01-30 2003-09-26 데이진 가부시키가이샤 의약 조성물
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
CA2447693A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
PT1405638E (pt) * 2001-07-10 2011-04-06 Astellas Pharma Inc Composição farmacêutica compreendendo 1-fenil-1,2,3,4 tetrahidroisoquinolino- 2-carboxilato de quinuclidin-3'-ilo para tratamento de cistite intersticial e/ou prostatite não bacteriana
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
BR0315784A (pt) * 2002-10-29 2005-09-20 Pharmacia & Upjohn Co Llc Compostos de amÈnio quaternário
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US20060147531A1 (en) * 2003-07-01 2006-07-06 Mojca Segula Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
KR101836467B1 (ko) * 2004-03-25 2018-03-08 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof

Also Published As

Publication number Publication date
CN101141961A (zh) 2008-03-12
US20080103171A1 (en) 2008-05-01
AU2005320672A1 (en) 2006-07-06
AU2005320672B2 (en) 2011-01-06
CN101141961B (zh) 2011-07-06
EP1832288B1 (en) 2012-06-20
CA2591761A1 (en) 2006-07-06
EP1832288A4 (en) 2010-02-24
KR101342786B1 (ko) 2013-12-19
WO2006070735A1 (ja) 2006-07-06
KR20070098889A (ko) 2007-10-05
EP1832288A1 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
NO20073928L (no) Stabilt partikkelformig legemiddel med solifenacin eller salt av dette
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
EP4293009A3 (en) Fenfluramine compositions and methods of preparing the same
WO2006124490A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
TW200716202A (en) Pediatric formulation of topiramate
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
JP2018090566A5 (no)
DK1778680T3 (da) Spirocykliske cyclohexaderivater
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX2025000641A (es) Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
BRPI0515860B8 (pt) derivados de tetralin e indano, seus usos, e composição farmacêutica
EP1496836A4 (en) N- (SUBSTITUTED BENZYL) -8-HYDROXY-1,6-NAPHTHYRIDINE-7-CARBOXYLIC AMIDE AS HIV INTEGRASE INHIBITORS
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
SE0402635D0 (sv) Chemical compounds
WO2005072132A3 (en) TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF